Literature DB >> 7397631

Intensive five-drug combination chemotherapy for adult acute non-lymphocytic leukemia.

B A Peterson, C D Bloomfield, G J Bosl, G Gibbs, M Malloy.   

Abstract

Twenty-two newly diagnosed adults with acute non-lymphocytic leukemia (ANLL) and 18 who had relapsed from a prior complete remission (CR) obtained with intensive chemotherapy were treated with a combination of Adriamycin, cytosine arabinoside, 6-thioguanine, prednisone, and vincristine. Eighteen (82%) of the patients undergoing initial induction therapy, including 4 of 6 patients over 60 years of age, achieved CR. Twelve patients (67%) undergoing reinduction therapy also achieved CR. Twenty-three (77%) of the 30 CRs were obtained with only one course of chemotherapy. The median time to CR for those undergoing initial treatment was 32 days, and the median duration of CR is 10+ months. The median survival for all 22 newly diagnosed patients is 15+ months. This intensive five-drug regimen is highly effective for the remission induction of both newly diagnosed and previously treated patients with ANLL producing a high percentage of CRs with only one course of therapy.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7397631     DOI: 10.1002/1097-0142(19800815)46:4<663::aid-cncr2820460406>3.0.co;2-9

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

1.  A randomized trial of chemoimmunotherapy of acute nonlymphocytic leukemia in adults using a protein-bound polysaccharide preparation.

Authors:  R Ohno; K Yamada; T Masaoka; T Ohshima; I Amaki; Y Hirota; N Horikoshi; A Horiuchi; K Imai; I Kimura
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

2.  Intensified remission induction therapy for acute nonlymphocytic leukemia (ANLL). Treatment report on 60 patients.

Authors:  D Urbanitz; T Büchner; D Kamanabroo; W Hiddemann; H Schulte; J van de Loo
Journal:  Blut       Date:  1981-08

3.  Immunotherapy in the treatment of acute myelogenous leukemia (AML): rationale, results and future prospects.

Authors:  D Urbanitz; T Büchner; H Pielken; J van de Loo
Journal:  Klin Wochenschr       Date:  1983-10-03

4.  A phase II study of prednimustine in acute non-lymphocytic leukemia, smouldering leukemia, and refractory anemia with excess blasts.

Authors:  D R Gandara; C A Ries; S A Schiff; C B George; J P Lewis; M M Koretz; S K Carter
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.